Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.
PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.
PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
Learn more about Who We Are.
Michael J. Fox has created an exclusive video thanking the PPMI volunteers and researchers for their exceptional contributions to Parkinson’s research.
PPMI has been actively collecting a wealth of biospecimens from the study participants, a group that has now grown to over 800 enrolled individuals. The samples are standardized, longitudinal, and available to qualified researchers conducting biomarker verification studies.
PPMI’s principal investigator, Dr. Ken Marek, will present on the initial findings of PPMI at the 8th Annual Parkinson’s Disease Therapeutics Conference on October 29 in New York City.
The audio from the latest PPMI Participant Study Update Call has just been posted. On the call, the principal investigator of the PPMI Imaging Core, John Seibyl, MD of Molecular Neuroimaging, LLC, discusses the role of imaging in PPMI. Listen to this call and find an archive of the past calls here.
A new study using PPMI data was published in the journal Movement Disorders exploring the relationship between cognitive impairment and dopaminergic deficits in unmedicated Parkinson’s patients.